• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . Risk of neuropsychiatric and related conditions associated with SARS-CoV-2 infection: a difference-in-differences analysis

tetano

Editor, Senior Moderator
Nat Commun


. 2025 Jul 24;16(1):6829.
doi: 10.1038/s41467-025-61961-1. Risk of neuropsychiatric and related conditions associated with SARS-CoV-2 infection: a difference-in-differences analysis

Yiwen Lu[SUP] #[/SUP][SUP] 1 2 [/SUP], Jiayi Tong[SUP] #[/SUP][SUP] 1 3 4 [/SUP], Dazheng Zhang[SUP] #[/SUP][SUP] 1 3 [/SUP], Jiajie Chen[SUP] 1 3 [/SUP], Lu Li[SUP] 1 2 [/SUP], Yuqing Lei[SUP] 1 3 [/SUP], Ting Zhou[SUP] 1 3 [/SUP], Leyna V Aragon[SUP] 5 6 [/SUP], Michael J Becich[SUP] 7 [/SUP], Saul Blecker[SUP] 8 [/SUP], Nathan J Blum[SUP] 9 [/SUP], Dimitri A Christakis[SUP] 10 [/SUP], Mady Hornig[SUP] 5 11 [/SUP], Maxwell M Hornig-Rohan[SUP] 5 [/SUP], Ravi Jhaveri[SUP] 12 [/SUP], W Schuyler Jones[SUP] 13 [/SUP], Amber Brown Keebler[SUP] 14 [/SUP], Kelly Kelleher[SUP] 15 [/SUP], Susan Kim[SUP] 16 [/SUP], Abu Saleh Mohammad Mosa[SUP] 17 18 [/SUP], Kathleen Pajer[SUP] 19 [/SUP], Jonathan Platt[SUP] 20 [/SUP], Hayden T Schwenk[SUP] 21 [/SUP], Bradley W Taylor[SUP] 22 [/SUP], Levon H Utidjian[SUP] 23 [/SUP], David A Williams[SUP] 24 [/SUP], Raghuram Prasad[SUP] 25 [/SUP], Josephine Elia[SUP] 26 [/SUP], Christopher B Forrest[SUP] 23 [/SUP], Yong Chen[SUP] 27 28 29 30 31 32 [/SUP]



Affiliations
Abstract

The COVID-19 pandemic has been associated with increased neuropsychiatric conditions in children and youths, with evidence suggesting that SARS-CoV-2 infection may contribute additional risks beyond pandemic stressors. This study aims to assess the full spectrum of neuropsychiatric conditions in COVID-19 positive children (ages 5-12) and youths (ages 12-20) compared to a matched COVID-19 negative cohort, accounting for factors influencing infection risk. Using EHR data from 25 institutions in the RECOVER program, we conduct a retrospective analysis of 326,074 COVID-19 positive and 887,314 negative participants matched for risk factors and stratified by age. Neuropsychiatric outcomes are examined 28 to 179 days post-infection or negative test between March 2020 and December 2022. SARS-CoV-2 positivity is confirmed via PCR, serology, or antigen tests, while negativity requires negative test results and no related diagnoses. Risk differences reveal higher frequencies of neuropsychiatric conditions in the COVID-19 positive cohort. Children face increased risks for anxiety, OCD, ADHD, autism, and other conditions, while youths exhibit elevated risks for anxiety, suicidality, depression, and related symptoms. These findings highlight SARS-CoV-2 infection as a potential contributor to neuropsychiatric risks, emphasizing the importance of research into tailored treatments and preventive strategies for affected individuals.


 
Back
Top Bottom